A Double Blind, Placebo Controlled, Randomised, First Time In Man. Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD8848 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out Of Season.

Trial Profile

A Double Blind, Placebo Controlled, Randomised, First Time In Man. Study to Investigate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of AZD8848 Administered Intranasally to Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out Of Season.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2015

At a glance

  • Drugs DSP 3025 (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions; Biomarker
  • Acronyms SAD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2009 Actual patient number (130) added as reported by ClinicalTrials.gov.
    • 10 Jun 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 10 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top